Skip to main content
. 2023 Oct 18;30(12):e230232. doi: 10.1530/ERC-23-0232

Figure 3.

Figure 3

BON1 cells were treated with different doses of cabozantinib or sunitinib (µM), for the indicated times. (A) Analysis of MET phosphorylation. (B) Analysis of mTOR pathway. (C) Analysis of MCL-1 levels.